Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis

Gregory, W. Herbert; Richards, M. A.; Malpas, J. S.

doi:10.1016/0140-6736(92)91996-l

Cited by 5 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Because the patient declined to undergo any aggressive chemotherapy, the MP therapy (10) consisting of 8 mg/m 2 melphalan on days 1–4 and 60 mg prednisone orally on days 1–4 was started as a palliative therapy. The shadow on X‐ray and clinical signs improved gradually.…”

Section: Case Reportmentioning

confidence: 99%

Pulmonary parenchymal infiltrates in a patient with CD20‐positive multiple myeloma

Yokote¹,

Akioka²,

Miyamoto³

et al. 2004

European J of Haematology

View full text Add to dashboard Cite

A 53-yr-old woman developed a dry cough after the completion of multi-agent chemotherapy. The biopsy specimens showed diffuse infiltrates with multiple myeloma (MM) cells. Immunohistochemistry revealed positive staining in MM cells with surface CD20, surface CD38, and cytoplasmic IgG. This report represents the first reported case of pulmonary parenchymal infiltrates in a patient with CD20-positive MM.

show abstract

Section: Case Reportmentioning

confidence: 99%

Pulmonary parenchymal infiltrates in a patient with CD20‐positive multiple myeloma

Yokote¹,

Akioka²,

Miyamoto³

et al. 2004

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Major responses have been reported for these drugs when combined with corticosteroids,2, 6 and a similar effect has been reported with high‐dose corticosteroids as single‐drug treatment 13. Large overviews of clinical studies also have failed to demonstrate any superiority of combination treatments, including vincristine and/or anthracyclines, compared with traditional oral MP 14, 15. Furthermore, in a recent study, alternating courses of VAD and MP were compared with MP alone.…”

Section: Discussionmentioning

confidence: 91%

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma

Mellqvist

Lenhoff

Johnsen

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexamethasone (VAD) was the most commonly used induction therapy before ASCT and yielded rapid major responses without interfering with stem cell harvest. However, the administration of VAD demands a central venous access, and well‐described toxicities are associated with the therapy. This randomized trial, which was initiated in 2001 by the Nordic Myeloma Study Group, was an attempt to bring a larger portion of patients to ASCT more quickly. METHODS Patients were randomized to receive either 3 cycles of VAD or 2 courses of cyclophosphamide plus dexamethasone (Cy‐Dex) (cyclophosphamide at a dose of 1000 mg/m2 on Day 1 and dexamethasone at a dose of 40 mg per day on Days 1–4 and 9–12, repeated on Day 22) as initial therapy followed by stem cell mobilization, harvest, and finally ASCT. RESULTS No significant difference was observed in the proportion of patients undergoing ASCT (VAD [86%] vs Cy‐Dex [87%]). During the first 4 months after the initiation of therapy, the mortality rates were 5.8% for VAD and 1.9% for Cy‐Dex (P = .08). The response rates after ASCT were comparable (partial response or better: VAD: 80% vs Cy‐Dex: 81%). In both groups, the median event‐free survival was 29 months, and the overall survival rate at 3 years was 75%. CONCLUSIONS The current results indicated that Cy‐Dex before ASCT has efficacy comparable to that of VAD. It also demonstrated that a short course of alkylator therapy using cyclophosphamide does not affect stem cell harvest or transplantation. Cancer 2008. © 2007 American Cancer Society.

show abstract

“…Myeloma cells are embedded in the bone marrow microenvironment which has been shown to support growth and drug resistance of myeloma cells. Despite the therapy with alkylating agents, anthracyclines, steroids and high dose regimes with autologous stem cell support, MM cells become resistant to common cytotoxic drugs and patients eventually die of tumour progression (1–3). To increase response rates, to overcome primary and secondary drug resistance and to avoid side effects, a combination of anti‐tumour agents is often preferred in the treatment of MM.…”

mentioning

confidence: 99%

Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs

Baumann¹,

Armann²,

Mandl-Weber³

et al. 2007

European J of Haematology

View full text Add to dashboard Cite

show abstract

Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis

Cited by 5 publications

References 7 publications

Pulmonary parenchymal infiltrates in a patient with CD20‐positive multiple myeloma

Pulmonary parenchymal infiltrates in a patient with CD20‐positive multiple myeloma

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma

Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs

Contact Info

Product

Resources

About